|
1) 厚生労働省大臣官房統計情報部: 人口動態統計. 厚生労働省ホームページ http://www.mhlw.go.jp/toukei/saikin/index.html
|
|
|
|
|
2) Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, version 2.0 IARC oress. Lyon; 2004
|
|
|
|
|
|
3) Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet. 2005; 366: 1303-14
|
|
|
|
|
4) Randi G, Franceschi S, Vecchia CL. Gallbladder cancer world wide: Geographical distibution and risk factors. Int J Cancer. 2006; 118: 1591-602
|
|
|
|
|
|
5) Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2008; 51: 349-64
|
|
|
|
|
|
6) Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: Recent progress. Part 1: Epidemiology and etiology. J Gastroenterol Hepatol. 2002; 17: 1049-55
|
|
|
|
|
|
7) Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004; 24: 115-25
|
|
|
|
|
|
8) Ishiguro S, Inoue M, Kurahashi N, et al. Risk factors of biliary tract cancer in a large-scale population-based cohort study in Japan (JPHC study): with speciual focus on cholelithiasis, body mass index, and their effect modification. Cancer Cause Control. 2008: 19: 33-41
|
|
|
|
|
|
9) Welzel TM, Graubard BI, EI-Serag HB, et al. Risk factors for intra- and extrahepatic cholangiocarcinoma in the United States: a population based case-control study. Clin Gastroenterol Hepatol. 2007; 5: 1221-8
|
|
|
|
|
|
10) Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer. 2000; 88: 2471-7
|
|
|
|
|
|
11) Wise C, Pilanthananond M, Perry BF, et al. Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol. 2008; 14: 2986-9
|
|
|
|
|
|
12) Sirica AE. Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy. Hepatology. 2005; 41: 5-15
|
|
|
|
|
|
13) Hassid V, Orlando FA, Awad ZT, et al. Genetic and molecular abnormalities in cholangiocarcinogenesis. Anticancer Res. 2009; 29: 1151-6
|
|
|
|
|
|
14) Fava G, Marzioni M, Benedetti A, et al. Molecular pathology of biliary tract cancers. Cancer Lett. 2007; 250: 155-67
|
|
|
|
|
|
15) 中沼安二, 佐藤保則, 佐々木素子, 他. 慢性胆管障害からみた肝内胆管癌のハイリスク因子. 肝胆膵. 2008; 57: 27-33
|
|
|
|
|
16) 正田純一, 石毛和紀, 杉山弘明, 他. 胆道癌における分子標的治療の可能性について. 胆道. 2009; 23: 762-74
|
|
|
|
|
17) Pinlaor S, Hiraku Y, Ma N, et al. Mechanism of NO-mediated oxidative and nitrative DNA damage in hamsters infected with opisthorchis viverrini: a model of inflammation-mediated carcinogenesis. Nitric Oxide. 2004; 11: 175-83
|
|
|
|
|
|
18) Miyahara N, Shoda J, Ishige K, et al. MUC4 Interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications. Eur J Cancer. 2008; 44: 1048-56
|
|
|
|
|
|
19) Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol. 2006; 45: 856-67
|
|
|
|
|
|
20) Blechachacz B, Gores GJ. Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008; 48: 308-21
|
|
|
|
|
|
21) Zen Y, Fujii T, Itatsu K, et al. Biliary cystic tumors with bile duct communication: a cystic variant of intraductal papillary neoplasm of the bile duct. Mod Pathol. 2006; 19: 1243-54
|
|
|
|
|
|
22) Zen Y, Fujii T, Itatsu K, et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology. 2006; 44: 1333-43
|
|
|
|
|
|
23) Tanimura Y, Kokuryo T, Tsunoda N, et al. Tumor necrosis factor alpha promotes invasiveness of cholangiocarcinoma cells via its receptor, TNFR2. Cancer Lett. 2005; 219: 205-13
|
|
|
|
|
|
24) Sasaki M, Yamaguchi J, Itatsuku, et al. Overexpression of polyclomb group protein EZH2 relates to decreased expression of p16INK4a in cholangiocarcinogenesis in hepatolithiasis. J Pathol. 2008; 215: 175-83
|
|
|
|
|
|
25) Zen Y, Sasaki M, Fujita T, et al. Differential expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct―an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol. 2006; 44: 350-8
|
|
|
|
|
|
26) Marzioni M, Fava G, Benedetti A. Nervous and neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis. World J Gastroenterol. 2006; 12: 3471-80
|
|
|
|
|
|
27) Alvaro D, Barbaro B, Franchitto A, et al. Estrogen and insulin-like growth factor1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol. 2006; 169: 877-88
|
|
|
|
|
|
28) Itatsu K, Sasaki M, Yamaguchi J, et al. Cyckooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha. Am J Pathol. 2009; 174: 829-41
|
|
|
|
|
|
29) Onodera M, Zen Y, Harada K, et al. Fascin is involved in tumor necrosis factor-alpha-dependent production of MMP9 in cholangiocarcinoma. Lab Invest. 2009; 89: 1241-61
|
|
|
|
|
|
30) Ohira S, Sasaki M, Harada K, et al. Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. Am J Pathol. 2006; 168: 1155-68
|
|
|
|
|
|
31) Ohira S, Itstsu K, Sasaki M, et al. Local balance of transforming growth factor-beta1 secreted from cholangiocarcinoma cells and strom-derived factor-1 secreted from stromal fibroblasts is a factor involved in invasion of cholangiocarcinoma. Pathol Int. 2006; 56: 381-9
|
|
|
|
|
|
32) Yoshikawa D, Ojima H, Iwasaki M, et al. Cliniopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008; 98: 418-25
|
|
|
|
|
|
33) Kiguchi K, Carbajal S, Chan K, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res. 2001; 61: 6971-6
|
|
|
|
|
|
34) Kiguchi K, Ruffino L, Kawamoto T, et al. Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. Clin Cancer Res. 2005; 11: 5572-80
|
|
|
|
|
|
35) Kiguchi K, Ruffino L, Kawamoto T, et al. Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5. ErbB-2 mice. Mol Cancer Ther. 2007; 6: 1709-17
|
|
|
|
|
|
36) Xu X, Kobayashi S, Qiao W, et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific dusruption of Smad4 and Pten in mice. J Clin Invest. 2006; 116: 1843-52
|
|
|
|
|